Paperonium

Cancer drugs · Clin Cancer Res · 2025

Summary: 2 in 3 patients in one group had severe fatigue. The paper’s table: none did.

Severe fatigue, both drugs0%Its own table: 0 of 1566.7%The summarytoo high0%20406080
Severe fatigue, both drugs0%Its own table: 0 of 1566.7%The summarytoo high0%20406080

Share with severe fatigue among the 15 patients on both drugs

The paper says

A cancer drug injected into tumours was tested alone (21 patients) and with a second drug (15 patients, then 41 more). The summary says the commonest severe drug-caused side effects were fatigue (28.6% alone, 66.7% with both drugs) and, among the 41, injection-site pain (31.7%).

Its own data show

In the paper’s own table, those three rates are the share of patients with the complaint at any severity, even mild, and whatever its cause: 6 of 21, 10 of 15 and 13 of 41. The same table’s severe counts: fatigue 0 of 21 and 0 of 15; injection-site pain 1 of 41 (2.4%).

Doctors grade side effects from mild to severe: 10 of 15 patients had fatigue, but none had it severely. The table counts cases from every cause, so zero severe cases means zero from the drug. These are the summary’s only safety numbers, and safety was a main aim; they sit uneasily with the paper’s conclusion that patients generally coped well.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors · Clin Cancer Res (2025) · doi:10.1158/1078-0432.CCR-24-1983